Uni Bio Science Group, Ltd. 0690
HKEX · Hong Kong SAR China · Health Technology
HKD 0.0700-0.00 (-1.41%)
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Spiral Therapeutics, Inc. ("Spiral Therapeutics" or "Spiral"), a clinical-stage company developing novel therapies for inner ear disorders, today announced the closing of its $27 million Series B financing. The financing, led by Gund Investment, includes new strategic participation from Advanced Bionics and a major global pharmaceutical company, alongside continued participation from Ferring Ventures, Uni-Bio Science Group and other existing investors.
As global markets keep a close watch on the Federal Reserve's final meeting of the year, Asian markets are also navigating their own set of economic signals, such as manufacturing slowdowns and service sector expansions. In this context, penny stocks—often smaller or newer companies—continue to hold relevance as potential growth opportunities. Despite being an outdated term for some, these stocks can offer significant upside when backed by strong financial health and fundamentals.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.